2023
Triple-Hormone-Receptor Agonist Retatrutide for Obesity. Reply.
Jastreboff A, Kaplan L, Hartman M. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. Reply. New England Journal Of Medicine 2023, 389: 1629-1630. PMID: 37888927, DOI: 10.1056/nejmc2310645.Peer-Reviewed Original ResearchNaltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial
Grilo C, Lydecker J, Jastreboff A, Pittman B, McKee S. Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial. Obesity 2023, 31: 2762-2773. PMID: 37751990, PMCID: PMC10600891, DOI: 10.1002/oby.23898.Peer-Reviewed Original ResearchConceptsNaltrexone/bupropionBinge-eating disorderObesity statusLogistic regressionWeight lossPlacebo-controlled trialWeight loss outcomesPrevalent psychiatric disordersEvidence-based treatmentsPost-treatment assessmentBinge-eating frequencyGreater percentage weight lossMedication outcomesRemission ratePharmacological optionsPlaceboBupropionPsychiatric disordersPercentage weight lossMixed modelsDisordersObesityPatientsSignificant reductionWeight reductionReducing BMI below the obesity threshold in adolescents treated with once‐weekly subcutaneous semaglutide 2.4 mg
Kelly A, Arslanian S, Hesse D, Iversen A, Körner A, Schmidt S, Sørrig R, Weghuber D, Jastreboff A. Reducing BMI below the obesity threshold in adolescents treated with once‐weekly subcutaneous semaglutide 2.4 mg. Obesity 2023, 31: 2139-2149. PMID: 37196421, DOI: 10.1002/oby.23808.Peer-Reviewed Original ResearchConceptsWeekly subcutaneous semaglutideBMI categoriesSubcutaneous semaglutideWeek 68Glucagon-like peptide-1 receptor agonistsObesity thresholdPeptide-1 receptor agonistsHigh-intensity physical activityObesity class IIIOverweight BMI categoryLogistic regression modelsOverweight BMIReceiving placeboTeens trialLifestyle interventionReceptor agonistPhysical activityPlaceboBMISemaglutideParticipants' BMIClass IIIOverall populationPhase 3aHealthy nutritionRetatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Rosenstock J, Frias J, Jastreboff A, Du Y, Lou J, Gurbuz S, Thomas M, Hartman M, Haupt A, Milicevic Z, Coskun T. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet 2023, 402: 529-544. PMID: 37385280, DOI: 10.1016/s0140-6736(23)01053-x.Peer-Reviewed Original ResearchConceptsGlucose-dependent insulinotropic polypeptideType 2 diabetesGLP-1 receptor agonistsEscalation groupPhase 2 trialReceptor agonistDulaglutide groupPlacebo groupStudy treatmentGLP-1Interactive web response systemModerate gastrointestinal adverse eventsType 2 diabetes managementCurrent consensus guidelinesGastrointestinal adverse eventsWeb response systemPhase 1 studyStudy site personnelHealth care centersGlucagon receptor agonistPhase 3 programRange of dosesPhase 2 dataBaseline HbAGlycaemic targetsTirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
Garvey W, Frias J, Jastreboff A, le Roux C, Sattar N, Aizenberg D, Mao H, Zhang S, Ahmad N, Bunck M, Benabbad I, Zhang X, investigators S, Abalos F, Manghi F, Zaidman C, Vico M, Aizenberg D, Costanzo P, Serra L, MacKinnon I, Hissa M, Vidotti M, Saraiva J, Alves B, Franco D, Moratto O, Murthy S, Goyal G, Yamasaki Y, Sato N, Inoue S, Asakura T, Shestakova M, Khaykina E, Troshina E, Vorokhobina N, Ametov A, Tu S, Yang C, Lee I, Huang C, Ou H, Freeman G, Machineni S, Klein K, Sultan S, Parsa A, Otero-Martinez J, Gonzalez A, Bhargava A, Brian S, Ince C, Plantholt S, Cole J, Lacour A, Vega D, de Souza J, Rohlf J, St. John R, Horowitz B, Audish H, Galindo R, Umpiperrez G, Ard J, Curtis B, Garvey W, Fraser N, Mandry J, Mohseni R, Mayfield R, Powell T, Vance C, Ong S, Lewy-Alterbaum A, Murray A, Al-Karadsheh A, Yacoub T, Roberts K, Fried D, Rosenstock J, Pulla B, Bode B, Frias J, Klaff L, Brazg R, Van J, Tan A, Briskin T, Rhee M, Chaicha-Brom T, Hartley P, Nunez L, Cortes-Maisonet G, Soucie G, Hsia S, Jones T. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet 2023, 402: 613-626. PMID: 37385275, DOI: 10.1016/s0140-6736(23)01200-x.Peer-Reviewed Original ResearchConceptsType 2 diabetesBody mass indexTreatment discontinuationAdverse eventsBodyweight reductionWeight managementGlucagon-like peptide-1 receptor agonistsInteractive web response systemPeptide-1 receptor agonistsGlucose-dependent insulinotropic polypeptideComputer-generated random sequenceFrequent adverse eventsPlacebo-controlled trialSerious adverse eventsIncretin-based therapiesPhase 3 trialWeb response systemTreatment of obesityWeekly tirzepatideCoprimary endpointsRescue therapySafety endpointWeek 72Safety profileStudy treatmentTriple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff A, Kaplan L, Frías J, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman M. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal Of Medicine 2023, 389: 514-526. PMID: 37366315, DOI: 10.1056/nejmoa2301972.Peer-Reviewed Original ResearchConceptsBody weightPercentage changePlacebo groupEnd pointGlucagon-like peptide-1Glucose-dependent insulinotropic polypeptideLower starting doseWeight-related conditionsCommon adverse eventsPlacebo-controlled trialPrimary end pointSecondary end pointsBody mass indexTreatment of obesityDose-dependent increaseDose-response relationshipWeight reductionStarting doseAdverse eventsInsulinotropic polypeptideHeart ratePeptide-1Side effectsGlucagon receptorWeeksAssociation between specific types of parent stressors and fast-food consumption among parents and children
Bautista T, Fogelman N, Lartigue S, Silverman W, Jastreboff A, Sinha R. Association between specific types of parent stressors and fast-food consumption among parents and children. Eating Behaviors 2023, 49: 101724. PMID: 37054487, PMCID: PMC10247538, DOI: 10.1016/j.eatbeh.2023.101724.Peer-Reviewed Original ResearchConceptsHousehold chaosParent stressorsYoung childrenOnly significant predictorSignificant predictorsFast food consumptionStress interventionsSeparate regression modelsParentsSpecific typesYear oldsChildrenStressorsFast food intakeChildren's fast food consumptionPredictorsFinal modelHealthy foodsOldsBehaviorStressInterventionTurnBody mass indexFindingsChampioning the use of people‐first language in childhood overweight and obesity to address weight bias and stigma: A joint statement from the European‐Childhood‐Obesity‐Group (ECOG), the European‐Coalition‐for‐People‐Living‐with‐Obesity (ECPO), the International‐Paediatric‐Association (IPA), Obesity‐Canada, the European‐Association‐for‐the‐Study‐of‐Obesity Childhood‐Obesity‐Task‐Force (EASO‐COTF), Obesity Action Coalition (OAC), The Obesity Society (TOS) and the World‐Obesity‐Federation (WOF)
Weghuber D, Khandpur N, Boyland E, Mazur A, Frelut M, Forslund A, Vlachopapadopoulou E, Erhardt É, Vania A, Molnar D, Ring‐Dimitriou S, Caroli M, Mooney V, Forhan M, Ramos‐Salas X, Pulungan A, Holms J, O'Malley G, Baker J, Jastreboff A, Baur L, Thivel D. Championing the use of people‐first language in childhood overweight and obesity to address weight bias and stigma: A joint statement from the European‐Childhood‐Obesity‐Group (ECOG), the European‐Coalition‐for‐People‐Living‐with‐Obesity (ECPO), the International‐Paediatric‐Association (IPA), Obesity‐Canada, the European‐Association‐for‐the‐Study‐of‐Obesity Childhood‐Obesity‐Task‐Force (EASO‐COTF), Obesity Action Coalition (OAC), The Obesity Society (TOS) and the World‐Obesity‐Federation (WOF). Pediatric Obesity 2023, 18: e13024. PMID: 37002830, DOI: 10.1111/ijpo.13024.Peer-Reviewed Original ResearchNew Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics
Jastreboff A, Kushner R. New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics. Annual Review Of Medicine 2023, 74: 125-139. PMID: 36706749, DOI: 10.1146/annurev-med-043021-014919.Peer-Reviewed Original ResearchConceptsGLP-1 RAsGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsAnti-obesity therapeuticsTreatment of obesityMechanism-based treatmentsNeurobiology of obesityObesity treatmentReceptor agonistGLP-1Obesity therapeuticsEffective treatmentObesityHalf of AmericansFirst agentTreatmentTherapeuticsAgonistsAgents
2022
"The Times They Are A-Changin'" at Diabetes Care.
Kahn S, Anderson C, Buse J, Selvin E, Angell S, Aroda V, Castle J, Cheng A, Danne T, Echouffo-Tcheugui J, Florez J, Gadgil M, Gastaldelli A, Green J, Jastreboff A, Kanaya A, Kandula N, Kovesdy C, Laiteerapong N, Nadeau K, Pop-Busui R, Powe C, Rebholz C, Rickels M, Sattar N, Shaw J, Sims E, Utzschneider K, Vella A, Zhang C. "The Times They Are A-Changin'" at Diabetes Care. Diabetes Care 2022, 46: 3-5. PMID: 36548704, DOI: 10.2337/dci22-0045.Peer-Reviewed Original ResearchDiabetes MellitusHumansClinical implications of Type 2 diabetes on outcomes after cardiac transplantation
Chouairi F, Mullan C, Ahmed A, Bhinder J, Guha A, Miller P, Jastreboff A, Fuery M, Chiravuri M, Geirsson A, Desai N, Maulion C, Sen S, Ahmad T, Anwer M. Clinical implications of Type 2 diabetes on outcomes after cardiac transplantation. PLOS ONE 2022, 17: e0273111. PMID: 36516178, PMCID: PMC9750001, DOI: 10.1371/journal.pone.0273111.Peer-Reviewed Original ResearchConceptsPost-transplant mortalityType 2 diabetesAllocation system changeOld allocation systemsHeart transplant recipientsOutcomes of patientsOrgan Sharing databaseProportion of patientsHeart transplantation outcomesLower likelihoodLikelihood of transplantationHigher likelihoodNew allocation systemCardiac transplantationHeart transplantationTransplant recipientsT2D patientsHeart failureSharing databaseCox regressionTransplantation outcomesUnited NetworkWorse outcomesT2DPatientsObstacles and opportunities in managing coexisting obesity and CKD: Report of a scientific workshop cosponsored by the National Kidney Foundation and The Obesity Society
Friedman AN, Schauer PR, Beddhu S, Kramer H, le Roux C, Purnell JQ, Sunwold D, Tuttle KR, Jastreboff AM, Kaplan LM. Obstacles and opportunities in managing coexisting obesity and CKD: Report of a scientific workshop cosponsored by the National Kidney Foundation and The Obesity Society. Obesity 2022, 30: 2340-2350. PMID: 36268562, DOI: 10.1002/oby.23599.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseNational Kidney FoundationManagement of obesityKidney diseaseMetabolic surgeryObesity managementKidney FoundationObesity SocietyWeight loss medicationsLifestyle interventionAdverse outcomesTransplant surgeryObesity medicineEffective treatmentObesityProvider engagementSurgeryBeneficial effectsMedicine expertsMultidisciplinary approachDiseasePatientsScientific workshopConclusionCollaborative action planObstacles and Opportunities in Managing Coexisting Obesity and CKD: Report of a Scientific Workshop Cosponsored by the National Kidney Foundation and The Obesity Society
Friedman AN, Schauer PR, Beddhu S, Kramer H, le Roux CW, Purnell JQ, Sunwold D, Tuttle KR, Jastreboff AM, Kaplan LM. Obstacles and Opportunities in Managing Coexisting Obesity and CKD: Report of a Scientific Workshop Cosponsored by the National Kidney Foundation and The Obesity Society. American Journal Of Kidney Diseases 2022, 80: 783-793. PMID: 36280397, DOI: 10.1053/j.ajkd.2022.06.007.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseNational Kidney FoundationKidney diseaseMetabolic surgeryObesity managementKidney FoundationObesity SocietyWeight loss medicationsManagement of obesityLifestyle interventionAdverse outcomesTransplant surgeryObesity medicineEffective treatmentObesityProvider engagementSurgeryBeneficial effectsMedicine expertsMultidisciplinary approachDiseasePatientsScientific workshopConclusionCollaborative action planTirzepatide Once Weekly for the Treatment of Obesity. Reply.
Jastreboff AM, Aronne LJ, Stefanski A. Tirzepatide Once Weekly for the Treatment of Obesity. Reply. New England Journal Of Medicine 2022, 387: 1434-1435. PMID: 36239655, DOI: 10.1056/nejmc2211120.Peer-Reviewed Original ResearchStress-level glucocorticoids increase fasting hunger and decrease cerebral blood flow in regions regulating eating
Bini J, Parikh L, Lacadie C, Hwang JJ, Shah S, Rosenberg SB, Seo D, Lam K, Hamza M, De Aguiar RB, Constable T, Sherwin RS, Sinha R, Jastreboff AM. Stress-level glucocorticoids increase fasting hunger and decrease cerebral blood flow in regions regulating eating. NeuroImage Clinical 2022, 36: 103202. PMID: 36126514, PMCID: PMC9486604, DOI: 10.1016/j.nicl.2022.103202.Peer-Reviewed Original ResearchConceptsCerebral blood flowRegional cerebral blood flowBlood flowMetabolic hormonesRandomized double-blind cross-over designDouble-blind cross-over designStress level glucocorticoidsPrimary sensory cortexPerfusion magnetic resonanceCross-over designMedial temporal gyrusWhole-brain voxelMedial brainstemSaline daysOvernight infusionCBF responseHunger ratingsPlasma insulinGlucocorticoid effectsHedonic signalsObesity riskLimbic regionsFood intakeNeural regulationDistinct brain networksParent Stress and Trauma, Autonomic Responses, and Negative Child Behaviors
Fogelman N, Schwartz J, Chaplin TM, Jastreboff AM, Silverman WK, Sinha R. Parent Stress and Trauma, Autonomic Responses, and Negative Child Behaviors. Child Psychiatry & Human Development 2022, 54: 1779-1788. PMID: 35674991, PMCID: PMC9729425, DOI: 10.1007/s10578-022-01377-w.Peer-Reviewed Original ResearchConceptsNegative child behaviorsTraumatic life eventsParent stressChild behaviorLife eventsParent-child interactionsChild behavioral outcomesGreater heart rate variabilityRecent life eventsChildren's attentionBehavioral outcomesHeart rate variabilityPhysiological copingYear old childrenLife stressAggressive behaviorCumulative stressOlder childrenMore parentsInteraction challengesAutonomic responsesParentsMajor lifeMore childrenChildrenTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal Of Medicine 2022, 387: 205-216. PMID: 35658024, DOI: 10.1056/nejmoa2206038.Peer-Reviewed Original ResearchConceptsBody weightTreatment discontinuationAdverse eventsGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsGlucose-dependent insulinotropic polypeptidePercentage changeDose escalation periodWeight-related complicationsCommon adverse eventsCoprimary end pointsBody mass indexSubstantial global morbidityTreatment of obesityMean percentage changePercentage of participantsMean body weightWeight reductionCardiometabolic measuresTreat populationPlacebo groupWeek 72Mean BMIWeekly dosesDose escalation
2021
Impact of Obesity on Heart Transplantation Outcomes
Chouairi F, Milner A, Sen S, Guha A, Stewart J, Jastreboff AM, Mori M, Clark KA, Miller PE, Fuery MA, Rogers JG, Notarianni A, Jacoby D, Maulion C, Anwer M, Geirsson A, Desai NR, Ahmad T, Mullan CW. Impact of Obesity on Heart Transplantation Outcomes. Journal Of The American Heart Association 2021, 10: e021346. PMID: 34854316, PMCID: PMC9075353, DOI: 10.1161/jaha.121.021346.Peer-Reviewed Original ResearchConceptsBody mass indexHigher BMI categoriesImpact of obesityHeart transplantation outcomesBMI categoriesTransplantation outcomesHeart transplantationHigher body mass indexAllocation system changeAdvanced heart failureOrgan Sharing databaseObese BMI categoriesVentricular assist deviceNew Organ ProcurementPosttransplant deathPosttransplantation deathPosttransplant mortalityBackground PatientsBMI 18.5Adult patientsCohort studyHeart failureHeart transplantSharing databaseWaitlist deathsTreating the Chronic Disease of Obesity
Gossmann M, Butsch WS, Jastreboff AM. Treating the Chronic Disease of Obesity. Medical Clinics Of North America 2021, 105: 983-1016. PMID: 34688422, DOI: 10.1016/j.mcna.2021.06.005.Peer-Reviewed Original ResearchConceptsChronic diseasesIntensive lifestyle interventionAvailable therapeutic modalitiesPrimary care providersTreatable chronic diseaseCare of patientsAntiobesity pharmacotherapiesBariatric surgeryLifestyle interventionSafe therapyComprehensive careTherapeutic modalitiesCare providersTreatment approachesObesityPatientsDiseaseCarePharmacotherapySurgeryTherapyDiagnosisCOVID‐19 vaccines are effective in people with obesity: A position statement from The Obesity Society
Butsch WS, Hajduk A, Cardel MI, Donahoo WT, Kyle TK, Stanford FC, Zeltser LM, Kotz CM, Jastreboff AM. COVID‐19 vaccines are effective in people with obesity: A position statement from The Obesity Society. Obesity 2021, 29: 1575-1579. PMID: 34212511, PMCID: PMC8441899, DOI: 10.1002/oby.23251.Peer-Reviewed Original ResearchConceptsCOVID-19 vaccineObesity SocietyCOVID-19-associated hospitalizationPosition statementEfficacy of vaccinesSARS-CoV-2Pfizer-BioNTechAvailable vaccinesUS FoodDrug AdministrationObesityVaccineEmergency useHigh efficacyPeer-reviewed literatureScientific evidenceCOVID-19EfficacyTime of publicationBriefing documentsDefinitive wayHospitalizationPatientsVaccinationAdministration